

Title (en)
DISEASE PREVENTION BY REACTIVATION OF THE THYMUS

Title (de)
PRÄVENTION VON KRANKHEITEN DURCH THYMUSREAKTIVIERUNG

Title (fr)
PREVENTION DE MALADIES PAR REACTIVATION DU THYMUS

Publication
EP 1363703 A2 20031126 (EN)

Application
EP 01986582 A 20011012

Priority

- AU PR074500 A 20001013
- IB 0102745 W 20011012
- US 79530200 A 20001013
- US 79528600 A 20001013
- US 75596501 A 20010105
- US 75598301 A 20010105
- US 75564601 A 20010105
- US 75891001 A 20010110
- US 96539501 A 20010926

Abstract (en)
[origin: WO0230259A2] The present disclosure provides methods for gene therapy utilizing hematopoietic stem cells, lymphoid progenitor cells, and/or myeloid progenitor cells. The cells are genetically modified to provide a gene that is expressed in these cells and their progeny after differentiation. In a preferred embodiment the cells contain a gene or gene fragment that confers to the cells resistance to HIV infection and/or replication. The cells are administered to a patient in conjunction with treatment to reactivate the patient's thymus. The cells may be autologous, syngeneic, allogeneic or xenogeneic, as tolerance to foreign cells is created in the patient during reactivation of the thymus. In a preferred embodiment the hematopoietic stem cells are CD34<+>. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In a preferred embodiment, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.

IPC 1-7
A61P 31/00

IPC 8 full level
A61P 31/00 (2006.01); **A61K 35/14** (2006.01); **A61K 35/15** (2015.01); **A61K 35/17** (2015.01); **A61K 35/28** (2006.01); **A61K 35/36** (2015.01); **A61K 38/08** (2006.01); **A61K 38/09** (2006.01); **A61K 38/18** (2006.01); **A61K 38/19** (2006.01); **A61K 38/20** (2006.01); **A61K 38/24** (2006.01); **A61K 39/00** (2006.01); **A61P 31/12** (2006.01); **A61P 31/18** (2006.01); **A61P 37/04** (2006.01); **A61P 37/06** (2006.01)

IPC 8 main group level
A61K (2006.01); **A61P** (2006.01)

CPC (source: EP)
A61K 35/28 (2013.01); **A61K 35/36** (2013.01); **A61K 38/09** (2013.01); **A61K 38/18** (2013.01); **A61K 38/1808** (2013.01); **A61K 38/1825** (2013.01); **A61K 38/193** (2013.01); **A61K 38/2013** (2013.01); **A61K 38/2046** (2013.01); **A61K 38/2086** (2013.01); **A61K 39/0006** (2013.01); **A61K 39/461** (2023.05); **A61K 39/464838** (2023.05); **A61P 31/00** (2018.01); **A61P 31/12** (2018.01); **A61P 31/18** (2018.01); **A61P 37/04** (2018.01); **A61P 37/06** (2018.01); **C12N 5/0647** (2013.01); **A61K 2239/38** (2023.05); **C12N 2510/00** (2013.01)

C-Set (source: EP)

1. **A61K 35/28 + A61K 2300/00**
2. **A61K 38/09 + A61K 2300/00**
3. **A61K 38/193 + A61K 2300/00**
4. **A61K 38/2013 + A61K 2300/00**
5. **A61K 38/2046 + A61K 2300/00**
6. **A61K 38/2086 + A61K 2300/00**
7. **A61K 38/1825 + A61K 2300/00**
8. **A61K 38/1808 + A61K 2300/00**
9. **A61K 38/18 + A61K 2300/00**
10. **A61K 35/36 + A61K 2300/00**
11. **A61K 39/464838 + A61K 2300/00**

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 0230259 A2 20020418; **WO 0230259 A3 20020704**; **WO 0230259 A9 20030807**; AP 2003002796 A0 20030630; AU 1632302 A 20020422; BR 0114642 A 20040120; CA 2462681 A1 20020418; CN 100406025 C 20080730; CN 1505537 A 20040616; EP 1363703 A2 20031126; EP 1363703 A4 20060607; IL 155414 A0 20031123; NZ 525830 A 20050729

DOCDB simple family (application)
IB 0102745 W 20011012; AP 2003002796 A 20011012; AU 1632302 A 20011012; BR 0114642 A 20011012; CA 2462681 A 20011012; CN 01820134 A 20011012; EP 01986582 A 20011012; IL 15541401 A 20011012; NZ 52583001 A 20011012